Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Gross Profit (2016 - 2025)

Historic Gross Profit for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Q3 2025 value amounting to $3.7 million.

  • Lineage Cell Therapeutics' Gross Profit fell 173.75% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.6 million, marking a year-over-year increase of 2775.56%. This contributed to the annual value of $9.2 million for FY2024, which is 1076.87% up from last year.
  • According to the latest figures from Q3 2025, Lineage Cell Therapeutics' Gross Profit is $3.7 million, which was down 173.75% from $2.7 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Gross Profit high stood at $5.1 million for Q1 2022, and its period low was $279000.0 during Q1 2021.
  • Its 5-year average for Gross Profit is $2.2 million, with a median of $1.8 million in 2023.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Gross Profit soared by 171397.85% in 2022, and later tumbled by 6102.06% in 2023.
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' Gross Profit stood at $964000.0 in 2021, then surged by 88.07% to $1.8 million in 2022, then grew by 1.05% to $1.8 million in 2023, then soared by 48.14% to $2.7 million in 2024, then skyrocketed by 35.45% to $3.7 million in 2025.
  • Its Gross Profit stands at $3.7 million for Q3 2025, versus $2.7 million for Q2 2025 and $1.5 million for Q1 2025.